Compare Motorola Solutions Inc (MSI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Summit Therapeutics Inc — how do they compare? Motorola Solutions Inc trades at $469.14 (market cap $77.26B), while Summit Therapeutics Inc trades at $15.27 (market cap $12.06B). The key difference: Motorola Solutions Inc is far larger — about 6.4× Summit Therapeutics Inc's market cap, and Motorola Solutions Inc pays a 1.04% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MSI | SMMT | |
|---|---|---|
Market Cap | $77.26B | $12.06B |
Sector | Technology | Health |
52-Week High | $490.30 | $26.98 |
52-Week Low | $363.83 | $12.55 |
Enterprise Value | $86.17B | $11.39B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $466.53, up 0.98% today, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.41 exceeding expectations, and the company raised its full-year guidance. Revenue growth is robust, supported by a record backlog of $15.6 billion, while profitability remains high with a net income margin of 17.44%.
The outlook is positive given strong demand in public safety and software services, though valuation multiples are elevated. Key risks include execution challenges and macroeconomic sensitivity. Analyst consensus is bullish with a $533.80 price target, implying significant upside from current levels.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
